 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 12/13/2000 | | | | Nymox Presents AlzheimAlert™ Test at Annual Meeting of American Academy of Anti-Aging
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
December 13, 2000: Nymox Pharmaceutical Corporation will make a feature presentation on the AlzheimAlert™ urinary test aid for the diagnosis of Alzheimer’s disease at the Annual Meeting of the American Academy of Anti-Aging in Las Vegas on December 16, 2000. Dr. Michael Munzar of Nymox will give a feature podium presentation on the most recent experience from the clinical use of the AlzheimAlert™ urine test. |
| 10/27/2000 | | | | Nymox Presents Positive Clinical Trial Data at Meeting of American Psychiatric Association
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
PHILADELPHIA, PA (October 27, 2000) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) – Positive trial data from Nymox’s Neural Thread Protein (NTP) Alzheimer test to aid the physician will be presented here at the current meeting of the American Psychiatric Association. Nymox’s NTP immunoassay was found to be 90% sensitive and over 90% specific in a study of 120 individuals. The data further validated the urine NTP test as a practical tool with significant clinical utility. |
| 10/26/2000 | | | | New Scientific Publication on Nymox Alzheimer Test
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
MAYWOOD, NJ (October 26, 2000) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) – Analysis of an independent study of Nymox’s Neural Thread Protein (NTP) test was published in the current issue of Neurology, the official journal of the American Academy of Neurology. New correspondence was published concerning the independent validation of NTP accuracy and measurement (Neurology 2000, 55, 1068). The study was undertaken in a multicenter coded trial of NTP at Stanford University School of Medicine, Departments of Neurobiology, Psychiatry and Behavioral Sciences, and Neurosurgery, the Parkinson’s Institute, and Ludwig-Maximilians University School of Medicine, Dementia Research and Neuroimaging Section, and Department of Psychiatry, that was published in the peer-reviewed journal. |
| 10/25/2000 | | | | Nymox Alzheimer Test Recommended in Anti-Aging Medical News
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
MAYWOOD, NJ (October 25, 2000) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) – A new article published in the Fall 2000 issue of the Anti-Aging Medical News has recommended Nymox’s urine test as an aid to the physician in testing for Alzheimer’s disease (AD). The Anti-Aging Medical News is the official publication of the American Academy of Anti-Aging. In reference to Nymox’s urinary neural thread protein (NTP) test the article states "a recent breakthrough in the laboratory investigation of dementia and Alzheimer’s disease may become a new standard for testing mental deterioration in the aging population". |
| 10/18/2000 | | | | Nymox Announces Launch of New AlzheimAlert™ Test
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
MAYWOOD, NJ (October 18, 2000) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that it has successfully developed a new test to aid in the diagnosis of Alzheimer’s disease. The new AlzheimAlertTM test will be launched and initially marketed from Nymox’s Clinical Reference Laboratory in Maywood, New Jersey. The Company further plans to file for regulatory approval where necessary to sell the new test kits to other laboratories. The AlzheimAlertTM test will be launched by Nymox’s recently announced new national sales force of 35 representatives. |
| 10/17/2000 | | | | Nymox Appoints Robert Rush Ph.D. D.A.B.C.C. as New Clinical Laboratory Director for Alzheimer's Diagnostic Aid
topic: Appointments
MAYWOOD, NJ (October 17, 2000) – Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced the appointment of Robert Rush Ph.D. D.A.B.C.C. as new Clinical Chemistry Laboratory Director for the Nymox Clinical Reference Laboratory in Maywood, New Jersey. Nymox’s Clinical Reference Laboratory is a CLIA federally certified facility that performs testing of urine samples submitted by physicians for measurements of neural thread protein (NTP), Nymox’s diagnostic aid to rule in or rule out Alzheimer’s disease. |
| 09/27/2000 | | | | Nymox Announces Marketing Launch with New Sales Force for Alzheimer Aid to Diagnosis
topic: Marketing
MAYWOOD, NJ (September 27, 2000) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that it has begun an extensive new marketing initiative for the 7C Gold test, Nymox’s unique urine test aid for the diagnosis or exclusion of Alzheimer’s disease. The Company has appointed a new Sales Executive with a new roster of 35 new sales representatives to promote the test in the U.S. |
| 09/25/2000 | | | | Nymox-Serex's Nicotine Test Shown to be Useful in Pediatric Second Hand Smoke Studies
topic: Tobacco Exposure Tests
MAYWOOD, NJ (September 25, 2000) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that recent studies have demonstrated that the Nymox-Serex nicotine dipstick test is a highly useful adjunct to smoking cessation regimes and for measurement of secondhand smoke exposure. |
| 09/21/2000 | | | | Nymox Appoints Suzanna Levy Ph.D. as Clinical Laboratory Scientific Director for Alzheimer's Diagnostic Aid
topic: Appointments
MAYWOOD, NJ (September 21, 2000) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced the appointment of Suzanne Levy Ph.D. as new Clinical Chemistry Laboratory Scientific-Director for the Nymox Clinical Reference Laboratory in Maywood, New Jersey. Nymox’s Clinical Reference Laboratory is a CLIA federally certified facility that performs testing of urine samples submitted by physicians for measurements of 7C Gold NTP, Nymox’s diagnostic aid to help rule in or rule out Alzheimer’s disease. |
| 09/20/2000 | | | | Nymox's Product Portfolio Well-Positioned to Provide Diagnostic Testing for Aging Baby Boomers
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
MAYWOOD, NJ (September 20, 2000) — Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today an update about the diagnostic services, technology and products available from the company and its subsidiaries for the benefit of our aging population. |
|